Medidata Rave Engage Wins Scrip Award for Best Sponsor-Focused Technological Development in Clinical Trials
November 30 2018 - 8:45AM
Business Wire
- Rave Engage Named Top Technology for
Sponsors at 14th Annual Scrip Awards
- Medidata Wins Prestigious Industry
Award for Third Consecutive Year
- Scrip Award Celebrates Innovation and
Excellence in Biopharmaceutical Industry
Medidata (NASDAQ:MDSO) is pleased to announce that Rave Engage
was recognized at the 2018 Scrip Awards as the "Best Technological
Development in Clinical Trials - Tech Sponsor Focused." This marks
the third consecutive Scrip Award win for the company.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20181130005221/en/
(Graphic: Business Wire)
Medidata Rave Engage is an intuitive web-based application that
serves as the patient-facing interface for virtual trials and
hybrid studies that seek to reduce physical site visits. Patients
remain engaged throughout the study with what Medidata calls the
“Trial Dial,” which enables sponsors to choose the right balance of
site-based and virtual visits. Through Rave Engage, sponsors and
investigators improve operational efficiency, scalability, and
patient recruitment and retention—all of which result in better
data and lower trial costs.
Presented to Medidata at the 14th Annual Scrip Awards on
November 28, 2018 in London, the award celebrates excellence and
innovation in the biopharmaceutical industry and a continued
commitment to improving healthcare on a global scale. A panel of
judges—comprised of independent, senior industry experts from
around the world—evaluated a record number of submissions across a
wide range of categories, announcing a shortlist of finalists
earlier this year.
“Medidata Rave Engage improves the entire patient and sponsor
experience with clinical trial virtualization,” said Anthony
Costello, vice president, mHealth, Medidata. “Modern clinical
trials, especially large-scale trials, need to be more efficiently
run and convenient for patients. We believe that virtual and hybrid
trials, made possible by Rave Engage and the Medidata platform, are
the future of clinical research.”
Rave Engage currently powers a number of virtual studies for
global pharmaceutical and biopharmaceutical companies, including
the well-publicized aspirin study, ADAPTABLE—the largest virtual
trial ever conducted, with an enrollment target of 15,000 patients.
With the Rave Engage platform, ADAPTABLE patients are virtually
enrolled, consented, and randomized to provide their own reported
outcome throughout the study with no physical site visits.
About Medidata
Medidata is leading the digital transformation of life sciences,
with the world's most used platform for clinical development,
commercial, and real-world data. Powered by artificial intelligence
and delivered by the #1 ranked industry experts, the Intelligent
Platform for Life Sciences helps pharmaceutical, biotech, medical
device companies, and academic researchers accelerate value,
minimize risk and optimize outcomes. Medidata serves more than
1,000 customers and partners worldwide and empowers more than
100,000 certified users every day to create hope for millions of
patients. Discover the future of life sciences: www.mdsol.com
View source
version on businesswire.com: https://www.businesswire.com/news/home/20181130005221/en/
Medidata SolutionsInvestors:Betsy Frank, +1
917-522-4620bfrank@mdsol.comMedia:Erik Snider, +1
646-362-2997esnider@mdsol.com
Medidata Solutions (NASDAQ:MDSO)
Historical Stock Chart
From Aug 2024 to Sep 2024
Medidata Solutions (NASDAQ:MDSO)
Historical Stock Chart
From Sep 2023 to Sep 2024